Coronavirus disease 2019 (COVID-19) is characterized by heterogeneity in susceptibility to
the disease and severity of illness. Understanding inter-individual variation has important …

The gut microbiome is emerging as an important contributor to both cardiovascular disease
risk and metabolism of xenobiotics. Alterations in the intestinal microbiota are associated …

High‐density‐lipoprotein cholesterol (HDL‐C) has been identified in population studies as
an independent inverse predictor of cardiovascular events. Although the causal nature of this …

Statins reduce cholesterol, prevent cardiovascular disease, and are among the most
commonly prescribed medications in the world. Statin‐associated musculoskeletal symptoms (…

Importance Implementation of pharmacogenetic testing to guide drug prescribing has potential
to improve drug response and prevent adverse events. Robust data exist for more than …

CYP2C19 genotype‐guided antiplatelet therapy following percutaneous coronary intervention
is increasingly implemented in clinical practice. However, challenges such as selecting a …

Background. Tacrolimus, a substrate of CYP3A, has low and variable bioavailability similar
to cyclosporine. Co-administration of ketoconazole, potent inhibitor of gut and hepatic CYP3A…

Importance Coronavirus disease 2019 (COVID-19) confers significant risk of acute kidney
injury (AKI). Patients with COVID-19 with AKI have high mortality rates. Objective Individuals …

Importance Current guidelines recommend prasugrel hydrochloride and ticagrelor hydrochloride
as preferred therapies for patients with acute coronary syndrome (ACS) treated with …

Aim: To examine community pharmacists‘ attitudes towards pharmacogenetic (PGx) testing,
including their views of the clinical utility of PGx and the ethical, social, legal and practical …